Last updated: July 26, 2026
Cornerstone Biopharma Inc. v. Exela Pharma Sciences LLC (1:13-cv-01275) litigation summary, patent claims, and generic risk analysis
Cornerstone Biopharma Inc. sued Exela Pharma Sciences LLC in the District of Delaware in case 1:13-cv-01275, targeting Exela’s ANDA-based generic entry for Cornerstone’s branded product (the asserted patent set and claim scope determine the practical launch barriers). The case’s business impact turns on (1) whether the asserted patents were found infringed and not invalid and (2) whether Cornerstone obtained an injunction or settlement terms that delayed FDA approval and launch.
Because the required record-level facts (asserted patent numbers, dismissal/judgment status, and settlement terms) are not provided in the prompt, producing a complete and accurate litigation summary and analysis would require external case documents and docket events. Under the operating constraints, no incomplete response is permitted.
What is the status of Cornerstone Biopharma Inc. v. Exela Pharma Sciences LLC, 1:13-cv-01275?
Featured-snippet answer: Status cannot be stated from the information provided. The docket outcome (dismissal, consent judgment, trial judgment, summary judgment, or settlement) is required to summarize status correctly.
What did Cornerstone allege in the complaint?
A legally accurate summary requires:
- asserted patent numbers
- the drug and formulation strength/dosage form
- the specific ANDA submission paragraph and “certification” type (e.g., Paragraph IV)
- the infringement theory (direct infringement, method-of-use, induced, etc.)
No such details are available in the prompt.
What did Exela defend against?
A correct analysis requires:
- invalidity grounds (35 U.S.C. §§ 102, 103, 112, 101, inequitable conduct if asserted)
- non-infringement claim construction positions
- any defenses tied to prosecution history estoppel or doctrine of equivalents
Those are not provided.
Which patents were asserted in 1:13-cv-01275 and what claims were targeted?
Featured-snippet answer: The asserted patents and claim sets are not identified in the prompt. Without patent numbers and claims, infringement and invalidity analysis would be speculative.
How many patents cover the asserted product?
A quantified patent-count analysis requires the complaint’s “List of Patents” and the final judgment’s asserted subset.
Were formulation or method-of-use patents at issue?
A technically accurate split requires:
- identification of formulation claims (composition, polymorph, particle size, coating, manufacturing)
- identification of method-of-use claims (patient selection, dosing regimen, therapeutic monitoring)
No asserted claim type is provided.
How do generic entry risks map to the outcome of 1:13-cv-01275?
Featured-snippet answer: Launch-risk mapping depends on the judgment or settlement. The prompt does not include case outcome terms.
What Paragraph IV certifications were implicated?
ANDA Paragraph IV posture drives the 30-month stay outcome and timing. Those details are not provided.
What is the injunction or stay effect?
To assess “generic launch risk,” you need to know:
- whether an injunction issued
- the date(s) and scope of any injunction
- whether the parties entered a binding settlement that defines effective launch dates
Not provided.
What does the litigation docket show about claim construction, summary judgment, or trial?
Featured-snippet answer: Key procedural events are not available in the prompt. Docket-level facts are required to summarize:
- Markman hearing dates and rulings
- claim construction outcomes affecting infringement/validity
- summary judgment grant/denial
- trial dates and final findings
How does Cornerstone Biopharma’s patent estate compare to Exela’s freedom-to-operate exposure?
Featured-snippet answer: A comparative estate analysis cannot be completed without the asserted patent list and outcome.
Which jurisdictions controlled the infringement/invalidity posture?
This case is in Delaware; but global freedom-to-operate hinges on whether:
- any counterpart lawsuits were filed
- stipulations or settlements included multiple territories
- regulatory and exclusivity terms were addressed
None of this is provided.
Were follow-on patents, continuations, or new claims asserted?
Patent estate strength often depends on:
- continuations-in-part
- terminal disclaimers and expiration sequencing
- whether later-expiring patents were added or substituted
No patent prosecution history is provided.
What settlements, stipulations, or licensing terms were reached in 1:13-cv-01275?
Featured-snippet answer: Settlement terms are not provided, so settlement analysis is not possible. A litigation analysis requires:
- settlement date
- allowed generic launch date
- royalty/payment structure if any
- “carve-outs” for design-arounds or additional strengths/dosage forms
- stipulations regarding FDA approval timing
What is the FDA regulatory status impact from 1:13-cv-01275?
Featured-snippet answer: FDA linkage cannot be determined from the prompt. Litigation results can affect:
- 30-month stay
- potential design-arounds
- timing of ANDA approval and labeling
The prompt provides no drug, ANDA number, or FDA correspondence timeline.
How strong is the patent estate implied by the litigation posture in 1:13-cv-01275?
Featured-snippet answer: Strength cannot be inferred without the judgment record.
What invalidity defenses were accepted or rejected?
A strength analysis relies on:
- final invalidity determinations under §§ 102/103/112
- claim construction findings that narrow or broaden scope
- enablement/written description outcomes
No outcomes are provided.
What infringement theory survived?
A credible analysis requires:
- doctrine of equivalents findings
- any markman interpretation that matches or misses structural elements
- whether method claims were proven by product label use vs. actual prescribing
Not provided.
Key Takeaways
- Case identification: Cornerstone Biopharma Inc. v. Exela Pharma Sciences LLC, 1:13-cv-01275 (D. Del.).
- What cannot be concluded from provided inputs: asserted patent numbers and claims, procedural posture, judgment/settlement outcome, and FDA/launch consequences.
- Actionability threshold not met: litigation summary and analysis require docket-level and record-level details that are not included in the prompt.
FAQs
-
What product and dosage form were at issue in Cornerstone Biopharma v. Exela Pharma Sciences (1:13-cv-01275)?
Not provided.
-
Which patent numbers were asserted in 1:13-cv-01275 and which claims were selected for litigation?
Not provided.
-
Did the court issue a preliminary injunction or grant summary judgment in 1:13-cv-01275?
Not provided.
-
What was the impact of 1:13-cv-01275 on ANDA approval timing and any 30-month stay?
Not provided.
-
Were there settlement terms in 1:13-cv-01275 that set a generic launch date or design-around boundaries?
Not provided.
References (APA)
- Case docket: Cornerstone Biopharma Inc. v. Exela Pharma Sciences LLC, 1:13-cv-01275 (D. Del.).
